Clover Health Investments Corp [NASDAQ: CLOV] jumped around 0.17 points on Friday, while shares priced at $2.83 at the close of the session, up 6.39%.
Compared to the average trading volume of 5.80M shares, CLOV reached a trading volume of 13045546 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
What do top market gurus say about Clover Health Investments Corp [CLOV]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLOV shares is $2.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLOV stock is a recommendation set at 2.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cowen have made an estimate for Clover Health Investments Corp shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on February 02, 2022. While these analysts kept the previous recommendation, Canaccord Genuity raised their target price to Buy. The new note on the price target was released on February 02, 2022, representing the official price target for Clover Health Investments Corp stock. Previously, the target price had yet another raise to $3, while SVB Leerink analysts kept a Mkt Perform rating on CLOV stock. On January 10, 2022, analysts decreased their price target for CLOV shares from 9 to 3.50.
The Average True Range (ATR) for Clover Health Investments Corp is set at 0.19, with the Price to Sales ratio for CLOV stock in the period of the last 12 months amounting to 0.83. The Price to Book ratio for the last quarter was 4.19.
How has CLOV stock performed recently?
Clover Health Investments Corp [CLOV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 52.15. With this latest performance, CLOV shares gained by 67.46% in over the last four-week period, additionally plugging by 180.20% over the last 6 months – not to mention a rise of 100.71% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLOV stock in for the last two-week period is set at 81.12, with the RSI for the last a single of trading hit 85.08, and the three-weeks RSI is set at 78.52 for Clover Health Investments Corp [CLOV]. The present Moving Average for the last 50 days of trading for this stock 1.54, while it was recorded at 2.37 for the last single week of trading, and 1.06 for the last 200 days.
Clover Health Investments Corp [CLOV]: Deeper insight into the fundamentals
Clover Health Investments Corp’s liquidity data is similarly interesting compelling, with a Current Ratio set at 1.69.
Earnings analysis for Clover Health Investments Corp [CLOV]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLOV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Clover Health Investments Corp go to 19.10%.
Insider trade positions for Clover Health Investments Corp [CLOV]
The top three institutional holders of CLOV stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in CLOV stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in CLOV stock with ownership which is approximately 5.1238%.
